These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12231172)

  • 1. Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector.
    Gilchrist SC; Ontell MP; Kochanek S; Clemens PR
    Mol Ther; 2002 Sep; 6(3):359-68. PubMed ID: 12231172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
    Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
    Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade.
    Jiang Z; Schiedner G; van Rooijen N; Liu CC; Kochanek S; Clemens PR
    Mol Ther; 2004 Oct; 10(4):688-96. PubMed ID: 15451453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes.
    Clemens PR; Kochanek S; Sunada Y; Chan S; Chen HH; Campbell KP; Caskey CT
    Gene Ther; 1996 Nov; 3(11):965-72. PubMed ID: 8940636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
    Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
    Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy.
    Wells DJ; Ferrer A; Wells KE
    Expert Rev Mol Med; 2002 Nov; 4(23):1-23. PubMed ID: 14585159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin.
    Gilbert R; Dudley RW; Liu AB; Petrof BJ; Nalbantoglu J; Karpati G
    Hum Mol Genet; 2003 Jun; 12(11):1287-99. PubMed ID: 12761044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle.
    Roberts ML; Wells DJ; Graham IR; Fabb SA; Hill VJ; Duisit G; Yuasa K; Takeda S; Cosset FL; Dickson G
    Hum Mol Genet; 2002 Jul; 11(15):1719-30. PubMed ID: 12095914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full-length dystrophin gene transfer to the mdx mouse in utero.
    Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
    Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
    Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
    Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy.
    Ho PP; Lahey LJ; Mourkioti F; Kraft PE; Filareto A; Brandt M; Magnusson KEG; Finn EE; Chamberlain JS; Robinson WH; Blau HM; Steinman L
    Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9182-E9191. PubMed ID: 30181272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence in muscle of an adenoviral vector that lacks all viral genes.
    Chen HH; Mack LM; Kelly R; Ontell M; Kochanek S; Clemens PR
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1645-50. PubMed ID: 9050832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector.
    Dudley RW; Lu Y; Gilbert R; Matecki S; Nalbantoglu J; Petrof BJ; Karpati G
    Hum Gene Ther; 2004 Feb; 15(2):145-56. PubMed ID: 14975187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
    J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant micro-genes and dystrophin viral vectors.
    Dickson G; Roberts ML; Wells DJ; Fabb SA
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S40-4. PubMed ID: 12206793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
    Ferrer A; Wells KE; Wells DJ
    Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
    Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
    Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.